Back to School

Starting from scratch

The formation of companies such as Human Genome Sciences Inc. and Millennium Pharmaceuticals Inc. with their roots in large-scale DNA sequencing may have been a one-time event. Such platforms are expensive to build.

Jonathan Rothberg, chairman and CEO of CuraGen Corp. (New Haven, Conn.), estimated that building CRGN's genome-wide discovery platform has cost $60 million over three years, while MLNM (Cambridge, Mass.) told BioCentury that it has spent about $100 million on technology since inception.